---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-24-000008"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:18:40.487189+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Curis Q4 2023 net loss $11.7M ($2.03/sh); cash $56.3M, clinical data from ASH shows CRs

## Summary
- Net loss for Q4 2023 was $11.7M ($2.03/share) vs $11.3M ($2.35/share) in Q4 2022.
- Revenue from Erivedge royalties was $2.7M for Q4 2023, flat YoY.
- Cash & investments totaled $56.3M at Dec 31, 2023; company expects runway into 2025.
- At ASH, emavusertib + ibrutinib achieved CR in 3 of 5 evaluable R/R PCNSL patients after BTKi failure.
- Updated TakeAim Leukemia data expected H1 2024; lymphoma combo and triplet combo data in H2 2024.

## SEC filing metadata
- accession: 0001108205-24-000008
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/0001108205-24-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/cris-20240208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-24-000008
- JSON: https://secwatch.observer/filing/0001108205-24-000008.json
- Plain text: https://secwatch.observer/filing/0001108205-24-000008.txt

## Key facts
- Earnings Releases
  CURIS INC reported financial results for full year and quarter ended December 31, 2023.
  - Period: full year and quarter ended December 31, 2023
  - Result: reported results
  source text: On February 8, 2024, Curis, Inc. announced its financial results for the full year and quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/0001108205-24-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.